VRDN - Viridian Therapeutics Inc. (VRDN) Q1 2024 Earnings Call Transcript
2024-05-08 14:27:10 ET
Viridian Therapeutics, Inc. (VRDN)
Q1 2024 Earnings Conference Call
May 8, 2024 8:00 AM ET
Company Participants
Louisa Stone – Manager of Investor Relations
Steve Mahoney – President and CEO
Tom Ciulla – Chief Medical Officer
Conference Call Participants
Laura Chico – Wedbush
Alex Thompson – Stifel
Michael Yee – Jefferies
Gavin Clark-Gartner – Evercore
Rami Katkhuda – LifeSci Capital
Gregory Renza – RBC
Julian Harrison – BTIG
Trevor Allred – Oppenheimer
Presentation
Operator
Welcome to the Viridian Therapeutics First Quarter 2024 Conference Call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session and instructions will be given at that time. [Operator Instructions] As a reminder, this conference call is being recorded.
I would now like to hand the call over to Ms. Louisa Stone, Manager of Investor Relations at Viridian. Please go ahead.
Louisa Stone
Thank you, and welcome, everyone, to our first quarter 2024 earnings conference call. The press release reporting our financial results and corporate updates is available on the Investors page of our corporate website at www.viridiantherapeutics.com. Joining me on the call this morning are Steve Mahoney, our President and CEO; Tom Ciulla, our Chief Medical Officer; and Shan Wu, our Chief Business Officer.
Before we begin, I would like to remind everyone that this conference call and webcast will contain forward-looking statements regarding our financial outlook in addition to regulatory, product development and commercialization plans and research activities.
These statements are subject to risks and uncertainties that could cause actual results to materially differ from those forecasted. A description of these risks can be found in our most recent Form 10-Q and 10-K on file with the SEC....
Viridian Therapeutics, Inc. (VRDN) Q1 2024 Earnings Call Transcript